Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. (Q45349601)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Zoltan Szallasi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Paul Lorigan

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ton Schumacher

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

Bianca Heemskerk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

21

Christian U Blank

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

19

John B A G Haanen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Sander Kelderman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Harm van Tinteren

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Rob R H van den Brom

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Geke A P Hospers

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alfonsus J M van den Eertwegh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Ellen W Kapiteijn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jan Willem B de Groot

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Patricia Soetekouw

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Rob L Jansen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Edward Fiets

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Andrew J S Furness

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Alexandra Renn

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Martin E Gore

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

James M G Larkin

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

8 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

63

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

449-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-014-1528-9

10 March 2020

exact match

0 references

cites work

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab: its potential in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1528-9

10.1007/S00262-014-1528-9

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

10 March 2020

1039731191

0 references

Fatcat ID

release_7hdaigatrzeqzaaekebhsixvui

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7hdaigatrzeqzaaekebhsixvui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24609989%20AND%20SRC:MED&resulttype=core&format=json